Education
About Us
Working with TipRanks
Follow Us
Avicanna (AVCNF)
OTHER OTC:AVCNF
Earnings Data
Report Date
Aug 18, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-0.01Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: 17.65%
|Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, successful platform performance, and significant advancements in R&D and international expansion. However, challenges such as a filing delay and continued net loss were noted. Overall, the positive achievements outweigh the lowlights.Company Guidance
In the recent call, Avicanna provided a comprehensive overview of its 2024 financial performance and strategic initiatives. The company reported record revenues of $25.5 million, marking a 52% increase from the previous year, with the MyMedi platform contributing approximately $21 million. Gross profits reached $12.9 million, reflecting a 94% increase, and gross margins improved to 51% from 40% in 2023. The adjusted EBITDA loss narrowed significantly to $1.4 million from $4.3 million, indicating progress toward profitability. Avicanna also highlighted its achievements in research and development, including its first pharmaceutical approval in Colombia and advancements in its pharmaceutical pipeline. Looking ahead, the company aims for further international expansion and plans to enhance its position in the cannabinoid-based medicine market, with a strategic focus on the European market and potential listing in the United States.Record Revenue Growth
The company achieved record revenues of $25.5 million, representing a 52% growth from the previous year. Gross profits were $12.9 million, a 94% increase from the previous year, with gross margins rising to 51%, a 40% increase from 2023.
Successful MyMedi Platform Performance
The MyMedi platform generated $21.7 million of gross revenue, reflecting strong adoption and a central role within the Canadian commercial strategy.
R&D and Pharmaceutical Advancements
Significant progress in R&D, including the first pharmaceutical approval with Trunerox in Colombia and advancements in the pharmaceutical pipeline with positive clinical results.
International Expansion
Completed transactions in 22 international markets and plans for further expansion, including the upcoming launch of Trunerox in Colombia and other South American markets.
Improved Financial Position
Narrowed EBITDA loss to $1.4 million from $4.3 million in 2023. Decreased liabilities and improved working capital deficit from $3.9 million to $1.6 million.
AVCNF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AVCNF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $0.17 | $0.19 | +11.76% |
Mar 31, 2025 | $0.23 | $0.19 | -17.39% |
Nov 14, 2024 | $0.17 | $0.17 | 0.00% |
Aug 14, 2024 | $0.24 | $0.27 | +12.50% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Avicanna (AVCNF) report earnings?
Avicanna (AVCNF) is schdueled to report earning on Aug 18, 2025, TBA Not Confirmed.
What is Avicanna (AVCNF) earnings time?
Avicanna (AVCNF) earnings time is at Aug 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AVCNF EPS forecast?
Currently, no data Available